Paul D. Allison

Paul D. Allison

Auto-generated profile, based on publicly available information

Paul D. Allison

Statistical Horizons LLC

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Socius: Sociological Research for a Dynamic World
Verified
Journal Article
Open access
PDF file
PAPaul D. Allison
Paul D. Allison
Standard fixed-effects methods presume that effects of variables are symmetric: The effect of increasing a variable is the same as the effect of decreasing that variable but in the opposite direction. This is implausible for many social phenomena. York and Light showed how to estimate asymmetric models by estimating first-difference regressions in which the difference scores for the predictors are decomposed into positive and negative changes. In this article, I show that there are several aspects of their method that need improvement. I also develop a data-generating model that justifies the first-difference method but can be applied in more general settings. In particular, it can be used to construct asymmetric logistic regression models.

24 December 2015
Verified
Book Chapter
Closed access
PDF file
DWDouglas Wiebe
Douglas Wiebe
TRTherese Richmond
Therese Richmond
JPJed Poster
Jed Poster
WGWensheng Guo
Wensheng Guo
PAPaul Allison
Paul Allison
CBCharles Branas
Charles Branas

16 January 2024
Verified
Dataset
Closed access
JLJacob A. Long
Jacob A. Long
RWRichard A. Williams
Richard A. Williams
PAPaul D. Allison
Paul D. Allison

1 June 2014 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
EAE. Alemao
E. Alemao
SJS. Joo
S. Joo
HKH. Kawabata
H. Kawabata
MAM. Al
M. Al
PAP. Allison
P. Allison
MWM.E. Weinblatt
M.E. Weinblatt
Background Recent studies, primarily in clinical trial settings, have suggested that attaining remission/low disease activity (LDA) in patients with early-stage RA contributes to improved clinical outcomes. Objectives Evaluate the associations between achievement of RA remission/LDA in clinical practice, as defined by Simplified Disease Activity Index (SDAI) <3.3, Clinical Disease Activity Index (CDAI) <2.8 and Disease Activity Score (DAS)28 (C-reactive protein; CRP) <2.6, and quality of life (QoL) measured by EQ5D and utilization of durable medical equipment (DME) and hospitalizations. Methods Patients enrolled in the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study (BRASS) Registry, established in 2003, were analysed to address the study objective. The BRASS Registry comprises mostly patients with established RA who were evaluated semi-annually on multiple clinical patient-reported outcomes and resource utilization parameters. The current analysis is based on the first 5 years of patient follow-up in BRASS. All independent variables including disease activity (SDAI, CDAI, DAS28-CRP) were measured prior to the outcomes. To control for intra-class correlation of the panel data in BRASS, mixed models were used to estimate the fixed effects on the outcomes, and the generalized estimating equations (GEE) method was utilized for bivariate outcomes, DME use and hospitalizations. Variables for the fixed effects included baseline demographics, co-morbidities, family history of disease, duration of RA disease, joint replacement, disease activity and seropositivity. Results A total of 1297 BRASS patients (82.3% female) were included. The mean (standard deviation [SD]) age of the study sample was 56.6 (14.1) years, with a mean (SD) duration of symptoms of 15.3 (13.0) years. Most (71.0%) patients were seropositive; 10.3% (n=134) and 7.0% (n=91) were in remission based on CDAI and SDAI criteria at baseline, respectively. A majority (95%) of patients were exposed to DMARDs and 45% of these were exposed to biologic DMARDs. After controlling for baseline covariates in the mixed models, improvements in EQ5D, DME use and hospitalizations were significantly associated with the attainment of remission/LDA versus moderate and severe disease activity (MDA and SDA, respectively), as defined by SDAI, CDAI, and DAS (see Table). Conclusions Attainment of remission or low disease activity in patients with RA in clinical practice is associated with improvement in quality of life, reduced durable medical equipment use and reduced hospitalizations. Disclosure of Interest E. Alemao Shareholder of: BMS, Employee of: BMS, S. Joo Shareholder of: BMS, Employee of: BMS, H. Kawabata Employee of: BMS, M. Al: None declared, P. Allison: None declared, M. Rutten-van Molken: None declared, M. Frits: None declared, C. Iannaccone: None declared, N. Shadick Grant/research support: ABBVIE, AMGEN, Genentech, M. Weinblatt Grant/research support: BMS, Crescendo Bioscience, UCB, Consultant for: BMS, Crescendo Bioscience, UCB, Abbvie, Roche, Janssen DOI 10.1136/annrheumdis-2014-eular.1897